Small molecule · Inhibitor · developed by Janssen Pharms
Itraconazole is an azole antifungal that inhibits the cytochrome P450-dependent synthesis of ergosterol, a vital component of fungal cell membranes. It is used to treat systemic fungal infections such as blastomycosis, histoplasmosis and aspergillosis, and dermatophyte infections of the nails. It is being studied in allergic bronchopulmonary aspergillosis (ABPA).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 13, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05667662 | Phase 2 | ABPA | Terminated | PULM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ABPA
Updated Oct 25, 2026.